UniPharma Group
www.unipharmagroup.comDistributor, Agent, Licensee for Pathelen Hybrid (Wound Powder) Pathelen® Woundpowder (Hybrid) – Pathelen is a new microporous silica powder, that adsorbs wound exudate, reducing the healing time of chronic wounds and offers a cost-effective alternative to the current treatment options for wounds. Pathelen® Hybrid (European Class 1 Certified Medical Device), a pioneering, side effect free treatment for open wound infections like MRSA, MDR, ESBL, and antibiotic-resistant bacteria (Superbugs), advancing existing capabilities of wound-care in public, private and military hospitals.
Read moreDistributor, Agent, Licensee for Pathelen Hybrid (Wound Powder) Pathelen® Woundpowder (Hybrid) – Pathelen is a new microporous silica powder, that adsorbs wound exudate, reducing the healing time of chronic wounds and offers a cost-effective alternative to the current treatment options for wounds. Pathelen® Hybrid (European Class 1 Certified Medical Device), a pioneering, side effect free treatment for open wound infections like MRSA, MDR, ESBL, and antibiotic-resistant bacteria (Superbugs), advancing existing capabilities of wound-care in public, private and military hospitals.
Read moreCountry
City (Headquarters)
London
Industry
Employees
11-50
Founded
2019
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Executive and Co - Founder
Email ****** @****.comPhone (***) ****-****Chief Operations Officer / Co - Founder
Email ****** @****.comPhone (***) ****-****Chief Communication and Development Officer ( Chief Compliance Officer and CDO )
Email ****** @****.comPhone (***) ****-****Chief Executive and Co - Founder
Email ****** @****.comPhone (***) ****-****
Technologies
(20)